TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05447910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study: NCT05553535

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: retrospective review of shoulder MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: retrospective review of shoulder MRI
Study: NCT04958291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: CC-99677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: CC-99677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: CC-99677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06307067

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine dipstick
Description: Urine dipstick is a point of care test that can be performed on the urine in the public health center.
Study: NCT05131932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ablation of inlet patch
Description: Endoscopic ablation of inlet patch using argon plasma coagulation (APC)
Study: NCT04373564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Tests
Description: To assess motor function annually

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Tests
Description: To assess motor function annually

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Motor Tests
Description: To assess motor function annually

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: To assess cognitive function annually

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: To assess cognitive function annually

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cognitive Tests
Description: To assess cognitive function annually

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unenhanced-MRI of the brain
Description: The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unenhanced-MRI of the brain
Description: The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unenhanced-MRI of the brain
Description: The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gadolinium Measurements
Description: Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gadolinium Measurements
Description: Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gadolinium Measurements
Description: Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
Study: NCT04800783

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Swallowing ultrasound
Description: Ultrasound assessment of the tongue movement and thickening, the geniohyoid and suprahyoid muscles echogenicity, thickness and thickening, the hyoid bone elevation, and the number of swallowing trial.
Study: NCT04373564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetate disodium
Description: Administered as defined by the treating physician as part of routine clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Description: Administered as defined by the treating physician as part of routine clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadodiamide
Description: Administered as defined by the treating physician as part of routine clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Description: Administered as defined by the treating physician as part of routine clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Administered as defined by the treating physician as part of routine clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Description: Administered as defined by the treating physician as part of routine clinical practice
Study: NCT05376904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034 midium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034 high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine HCl.
Description: ropivacaine HCl.
Study: NCT05718141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMET-GB
Description: Online self-guided single session intervention - comprised of 4 modules based on the core principles of CBT, combined with principles from positive psychology. Each module includes short reading exercises, informational videos, and writing exercises.~* Cognitive Restructuring (labelled Flexible Thinking)~* Behavioural Activation (labelled Positive Activities)~* Gratitude~* Self-Compassion~The initial intervention modules and assessment will take participants approximately 60-75 minutes to complete (15-20 minutes for the assessment measures only).
Study: NCT05559944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Participants will be asked to write about the biggest body image or eating-related stressor they have experienced as a member of the LGBTQ+ community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Affirmation
Description: Participants will receive one new vignette per day describing a SM young adult experiencing severe body image stress in Alabama. Participants will be asked to write to this person and provide advice based on their own experience as a SM young adult. Vignettes will be identical across participants; however, they will be matched to participants' sexual identity, gender identity, and race/ethnicity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Consistent with prior research participants will write about their routine daily activities since waking up for 20 minutes each day, sans emotional content.
Study: NCT06386900

Intervention type: OTHER
Intervention: Cyclist
Description: Participating in the Grand Tour as cyclist
Study: NCT05692804

Intervention type: DIAGNOSTIC_TEST
Intervention: Mini Mental State Examination(MMSE),Montreal Cognitive Assessment ( MoCA),S100B ( protein S100 subunit beta) ,GFAP ( glial fibrillary acidic protein ),NSE ( neuron-specific enolase )
Description: MMSE and MoCA will be applied preoperative,postoperative first day and fourth day S100B,GFAP and NSE will be measured in blood tests preoperative,postoperative second hour,postoperative 24. hour and postoperative 96. hour

Intervention type: DIAGNOSTIC_TEST
Intervention: Mini Mental State Examination(MMSE),Montreal Cognitive Assessment ( MoCA),S100B ( protein S100 subunit beta) ,GFAP ( glial fibrillary acidic protein ),NSE ( neuron-specific enolase )
Description: MMSE and MoCA will be applied preoperative,postoperative first day and fourth day S100B,GFAP and NSE will be measured in blood tests preoperative,postoperative second hour,postoperative 24. hour and postoperative 96. hour
Study: NCT06210815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX42
Description: HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT05427747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefotaxime
Description: One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~* Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~* Decrease of peritoneal fluid PMN count to \< 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefotaxime
Description: One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~* Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~* Decrease of peritoneal fluid PMN count to \< 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture.
Study: NCT04769739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CO2
Description: using CO2 insufflation to help insertion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: using water instead of traditional gas to help insertion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50% saline
Description: using 50% saline solution instead of traditional gas to help insertion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25% saline
Description: using 25% saline solution instead of traditional gas to help insertion
Study: NCT05487053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-shot adductor canal block
Description: Postoperative analgesia in this group will be carried out by a single-shot bolus of 20 ml Ropivacaine 0.5% in the region of the middle third of the adductor canal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block
Description: Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
Study: NCT04792372

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initial periodontal treatment
Description: Conventional periodontal treatment (scaling and root debridement) will be conducted
Study: NCT05282589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbopelvic manipulation and conventional therapy
Description: Lumbopelvic manipulation was given along with conventional physical therapy~Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes.
Study: NCT05029609

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Foralumab Solution
Description: The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Foralumab Solution
Description: The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Foralumab Solution
Description: The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Foralumab Solution
Description: The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
Study: NCT06000553

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.
Description: If the patient agrees to take part in the study, he or she will have a blood sample taken from 8 x 4 ml EDTA tubes at the time of inclusion in the trial.Then, at 6 months (+/- 1 month), 1 year and 2 years, the patient will have the same blood sample as at inclusion.If a biopsy is performed as part of routine care, a tumor sample will be taken and sent to the IPC pathology department for FFPE block. If a biopsy is performed and the patient consents, a cystic fluid sample will be taken.
Study: NCT05180981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Noninvasive stimulation vs sham stimulation will be delivered via an auricular device.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing task
Description: Participants will be asked to breathe in specific patterns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing task
Description: Participants will be asked to breathe in specific patterns.
Study: NCT04785768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride Injection
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride Injection
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate Sustained-release Tablets
Description: Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for day 1; 2）the total equianalgesic of the previous 24 hours/2 for day 2 ; 3）Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；4) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours;
Study: NCT05792761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b combined and ETV
Description: Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300.~1. NA monotherapy group : received entecavir (ETV) for 96 weeks.~2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks.~3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b combined and ETV
Description: Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300.~1. NA monotherapy group : received entecavir (ETV) for 96 weeks.~2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks.~3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b combined and ETV
Description: Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300.~1. NA monotherapy group : received entecavir (ETV) for 96 weeks.~2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks.~3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks.
Study: NCT06148402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib plus camrelizumab and capecitabine
Description: fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
Study: NCT04999605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 low dose
Description: AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 medium dose
Description: AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 high dose
Description: AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor
Study: NCT05585736

Intervention type: DRUG
Group type: OTHER
Intervention: Cycloplegics
Description: they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
Study: NCT05544318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diatary advices
Description: Advice regarding energy, protein and nutrient intake during cancer treatment
Study: NCT05974683

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
Study: NCT06194812

Intervention type: OTHER
Group type: OTHER
Intervention: Pain Catastrophizing scale
Description: Participants' fear and avoidance behaviors will be evaluated with the Fear Avoidance Beliefs Questionnaire (KKBS) (Appendix 2).~Participants' fear of movement will be evaluated with the Tampa Kinesiophobia Scale (TKS) (Appendix 3).~Pain Catastrophizing Scale (PAS) (Appendix 4) will be used to evaluate the participants' pain-related thoughts and feelings.~The amount of improvement in symptoms perceived by the participants will be evaluated at the end of the treatment with the Global Perceived Impact Scale (GAES) (Appendix 5). Participants were asked How would you describe your current situation compared to the beginning of treatment? question will be asked.
Study: NCT03582514

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative brain irradiation (single fraction)
Description: Dose and volume escalation of preoperative single-fraction radiotherapy.
Study: NCT05091619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine
Description: Intramuscular injection
Study: NCT04930653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: Undergo ECP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies